Skip to main content

menu
menu
person
Search

Specialty Program

Pain Management

Glycemic Regulation

PCSK9s in Interventional Cardiology

PCSK9s in Medical Preventative

PCSK9s in Lipid Medicine & Atherosclerosis Prevention

PCSK9s in Diabetes Management

PCSK9s: A Multi-Specialty Perspective

Specialty Program

Glycemic Regulation

PCSK9s in Diabetes Management

Specialty Program

Congenital Adrenal Hyperplasia (CAH)

Cytokine Immunotherapy

Specialty Program

Parkinson's Disease

Specialty Program

Cytokine Immunotherapy

Extracorporeal Photopheresis (ECP)

Pain Management

Specialty Program

Atopic Dermatitis

Congenital Adrenal Hyperplasia (CAH)

Parkinson's Disease

Pain Management

Glycemic Regulation

Specialty Program

Atopic Dermatitis

Cytokine Immunotherapy

Extracorporeal Photopheresis (ECP)

Specialty Program

Atopic Dermatitis

Cytokine Immunotherapy

Biosimilars for RA

PCSK9s in Interventional Cardiology

PCSK9s in Medical Preventative

PCSK9s in Lipid Medicine & Atherosclerosis Prevention

PCSK9s in Diabetes Management

PCSK9s: A Multi-Specialty Perspective

MAC Lung Disease

Specialty Program

MAC Lung Disease

close

person

Home
Specialties
- Topics
- Cardiology
- Diabetes
- Endocrinology
- Neurology
- Cancer
- Primary Care
- Dermatology
- Biologics
- MAC Lung Disease
Submit A Question

Freek W A Verheugt, MD, PhD

As the cost and institutional barriers to deploying PCSK9 inhibitors become less onerous, which patients in a medical cardiology practice represent the most attractive candidates for these agents and their profound LDL-C lowering effects?

As the cost and institutional barriers to deploying PCSK9 inhibitors become less onerous, which patients in a medical cardiology practice represent the most attractive candidates for these agents and their profound LDL-C lowering effects?

Freek W A Verheugt, MD, PhD

Based on the ODYSSEY Outcomes Trial, which enrolled primarily patients with post-ACS, which subset of patients managed in a medical cardiology practice should be thoroughly evaluated for CV risk reduction benefits accruing to PCSK9 inhibitors?

Based on the ODYSSEY Outcomes Trial, which enrolled primarily patients with post-ACS, which subset of patients managed in a medical cardiology practice should be thoroughly evaluated for CV risk reduction benefits accruing to PCSK9 inhibitors?

Freek W A Verheugt, MD, PhD

From your perspective as a medical cardiologist, what impact should the reductions in associated overall mortality reported with alirocumab in the ODYSSEY Outcomes Trial have on selecting a PCSK9 inhibitor?

From your perspective as a medical cardiologist, what impact should the reductions in associated overall mortality reported with alirocumab in the ODYSSEY Outcomes Trial have on selecting a PCSK9 inhibitor?

Freek W A Verheugt, MD, PhD

What would your approach be to a 57-year-old man with an LDL-C of 70 mg/dL who has recently had an ACS event and now develops recurrent ACS, or a new stent thrombosis? Does ODYSSEY Outcomes provide any evidence-based guidance?

What would your approach be to a 57-year-old man with an LDL-C of 70 mg/dL who has recently had an ACS event and now develops recurrent ACS, or a new stent thrombosis? Does ODYSSEY Outcomes provide any evidence-based guidance?

Freek W A Verheugt, MD, PhD

How have the results of ODYSSEY Outcomes—especially as they relate to progressive CV risk reductions in patients with high LDL-C levels who achieve target levels of 50 mg/dL or less—support the “treat-to-target” approach to lipid management?

How have the results of ODYSSEY Outcomes—especially as they relate to progressive CV risk reductions in patients with high LDL-C levels who achieve target levels of 50 mg/dL or less—support the “treat-to-target” approach to lipid management?

Freek W A Verheugt, MD, PhD

In the subpopulation of high-risk patients—individuals with post-ACS, patients with diabetes, post-PCI and others—is there enough compelling evidence from the PCSK9 trials that the “LDL hypothesis” is a proven fact?

In the subpopulation of high-risk patients—individuals with post-ACS, patients with diabetes, post-PCI and others—is there enough compelling evidence from the PCSK9 trials that the “LDL hypothesis” is a proven fact?

Freek W A Verheugt, MD, PhD

Disclaimer:
Copyright © by CMEducation Resources, LLC All rights reserved. Content on this webcast reflects the opinions, output, and analyses of experts, investigators, educators, and clinicians whose activities for, while independent, are commercially supported by the sponsor noted at the start of each activity.
Content on this webcast is not meant to be, nor substitute for national guidelines or recommendations generated by professional, academic societies, colleges, or associations.
Content on this webcast is intended for educational value only. Its contents, analyses, and any recommendation made herein are intended to make scientific information and opinion available to health professionals, to stimulate thought, and further investigation. This webcast is not designed nor is any aspect of the contents here intended to provide advice regarding medical diagnosis or treatment for any individual case. Any decisions regarding diagnosis and/or management of any individual patient or group of patients should be made on individual basis after having consulted appropriate sources, whether they be appropriate consultants and/or guidelines and recommendations issued by national organizations, professional societies, governmental health organizations, or similar bodies. This webcast is not intended for use by the layman.
Opinions expressed herein are not necessarily those of CMEducation Resources, LLC, program supporters or accreditors, but reflect the opinions and analyses of the experts who have authored the material. Mention of products or services does not constitute endorsement. Clinical, legal, financial, and other comments are offered for general guidance only; and professional counsel should be sought for all specific situations.

Clinical Webcasts®

Powered by BROADCASTMED